Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens
M. R. Schlabach, S. Lin, Z. Collester, C. Wrockage, S. Shenker, C. Calnan, T. Xu, H. Gannon, L. Williams, F. Thompson, P. Dunbar, R. LaMothe, T. E. Garrett, N. Colletti, A. Hohmann, , M. J. Benson
This study uses CRISPR/Cas9 screens to identify SOCS1 as a target for enhancing T cell therapy, leading to the development of an engineered TIL therapy with improved anti-tumor function.
bioRxiv · Sep 5, 2023 · PreprintImmunology